Showing results (11-20 of 68) with videos related to

Sort By:
Pageof 7
JCO Precision Oncology|August 11, 2022
SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor InhibitorsHiroki Sato, Daisuke Kubota, Huan Qiao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2021
Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 InsertionsNoura J Choudhury, Adam J Schoenfeld, Jessica Flynn, et al.
JAMA Internal Medicine|April 5, 2016
Variation in Quality of Urgent Health Care Provided During Commercial Virtual VisitsAdam J Schoenfeld, Jason M Davies, Ben J Marafino, et al.
Nature Communications|April 16, 2025
A clinical benchmark of public self-supervised pathology foundation modelsGabriele Campanella, Shengjia Chen, Manbir Singh, et al.
NPJ Precision Oncology|July 16, 2024
Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapyArielle Elkrief, Eder Orlando Méndez-Salazar, Jade Maillou, et al.
Nature Communications|June 18, 2021
Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancerKamrine E Poels, Adam J Schoenfeld, Alex Makhnin, et al.
JAMA Network Open|January 5, 2023
Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patents with Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and DurvalumabEmily S Lebow, Annemarie Shepherd, Jordan E Eichholz, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 1, 2019
Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK InhibitorsJessica J Lin, Adam J Schoenfeld, Viola W Zhu, et al.
BMC Cancer|September 2, 2025
A phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response in non-small cell lung cancer (HAMMER-NSCLC)Matthew T McMillan, Marsha Reyngold, Christopher H Crane, et al.
Medrxiv : the Preprint Server for Health Sciences|July 1, 2024
Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse eventsPooja Middha, Rohit Thummalapalli, Zoe Quandt, et al.
Pageof 7